

**10/552610**

**JCD9 Rec'd PCT/PTO 14 OCT 2001**

Express Mail Label No.

Dated: \_\_\_\_\_

Docket No.: 03981/0203467-US0  
(PATENT)

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Patent Application of:  
Gillian Smith et al.

Application No.: Not Yet Assigned

Confirmation No.: N/A

Filed: Concurrently Herewith

Art Unit: N/A

For: CYP2S1 AS TARGET DOR DIAGNOSIS  
AND THERAPY OF SKIN DISEASES

Examiner: Not Yet Assigned

**INFORMATION DISCLOSURE STATEMENT (IDS)**

MS PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the documents listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the documents be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement accompanies the new patent application submitted herewith.

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure statement shall not be construed to be an admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

10/552610

JC09 Rec'd PCT/PTO 14 OCT 2005

Docket No.: 03981/0203467-US0

Application No.: Not Yet Assigned

2

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed documents.

The Commissioner is authorized to charge any deficiency of up to \$300.00 or credit any excess in this fee to Deposit Account No. 04-0100.

Dated: October 4, 2005

Respectfully submitted,

By Paul F. Fehlner, Ph.D.

Registration No.: 35,135

DARBY & DARBY P.C.

P.O. Box 5257

New York, New York 10150-5257

(206) 262-8919

(212) 527-7701 (Fax)

Attorneys/Agents For Applicant

10/552610  
JC09 Rec'd PCT/PTO 14 OCT 2009

PTO/SB/08a/b (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>Substitute for form 1449A/B/PTO</b>				<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> <i>(Use as many sheets as necessary)</i>				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Gillian Smith
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	03981/0203467-US0

<b>U.S. PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

<b>FOREIGN PATENT DOCUMENTS</b>					
Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup> ( <i>if known</i> )	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
BA	WO-01/79468-A2		10-25-2001	Incyte Genomics, Inc.	
BB	WO-03/101376-A2		12-11-2003	L'oreal	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

<b>NON PATENT LITERATURE DOCUMENTS</b>					
Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.			
CA	Steven Rivera, et al.; "Identification of a Novel Dioxin-Inducible Cytochrome P450"; Molecular Pharmacology, vol. 61, no. 2, February 2002, pages 255-259.				
CB	Masayuki Furukawa, et al.; "Adenovirus Vector-Mediated Reporter System for <i>In Vivo</i> Analyses of Human CYP3A4 Gene Activation"; Journal of Biochemistry, Japanese Biochemical Society, Tokyo, Japan, vol. 131, no. 1, January 2002, pages 71-78.				
CC	Tove Rylander, et al.; "Identification and Tissue Distribution of the Novel Human Cytochrome P450 2S1 (CYP2S1)"; Biochemical and Biophysical Research Communications, vol. 281, no. 2, 23 February 2001, pages 529-535.				
CD	DATABASE EMBL 'Online! EBI; 23 October 2000, DOE JOINT GENOME INSTITUTE; XP002295655.				
CE	Gillain Smith, et al., "Cutaneous expression of cytochrome P450 CYP2S1: individuality in regulation by therapeutic agents for psoriasis and other skin diseases"; The Lancet, vol. 361, no. 9366, April 19, 2003, pages 1336-1343.				
CF	G. Smith, et al.; "Cytochrome P450 CYP2S1 expression in human skin: Individuality in regulation by therapeutic agents for psoriasis and other skin diseases"; British Journal of Dermatology, vol. 148, no. 4, April 2003, page 853.				

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature	Date Considered	
--------------------	-----------------	--